A SPECIFIC, SENSITIVE RADIOIMMUNOASSAY FOR PLATELET-ACTIVATING FACTOR (PAF)

被引：28
|
作者：
SMAL, MA
BALDO, BA
MCCASKILL, A
机构：
[1] ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA
[2] SILENUS LABS PTY LTD,HAWTHORN,VIC 3122,AUSTRALIA
[3] UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA
来源：
JOURNAL OF IMMUNOLOGICAL METHODS | 1990年 / 128卷 / 02期
关键词：
Anti-platelet-activating factor; Platelet-activating factor; Platelet-activating factor radioimmunoassay; Quantitation of platelet-activating factor;
D O I：
10.1016/0022-1759(90)90209-E
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
A specific radioimmunoassay (RIA) has been developed for platelet-activating factor (PAF) and shown to be sensitive over the range 10-1000 pg (0.02-2 pmol). The anti-PAF antibodies showed specificity for the acetyl group at the C2 position of the PAF molecule and exhibited no significant cross-reactivity with lyso-PAF or the naturally occurring lipids including lecithin and lysolecithin. The sensitivity of the RIA was at least as good as the platelet-based assays for PAF but the RIA was simpler to perform, had a higher capacity and did not have the drawback of the inherent variability associated with the bioassays. © 1990.
引用
收藏
页码：183 / 188
页数：6
相关论文
共 50 条
  • [41] ROLE OF PLATELET-ACTIVATING FACTOR (PAF) IN OVOIMPLANTATION AND DECIDUALIZATION PROCESS IN THE RAT
    ACKER, GM
    BRAQUET, P
    MENCIAHUERTA, JM
    PROSTAGLANDINS, 1988, 35 (05): : 817 - 817
  • [42] THE PRESENCE OF PLATELET-ACTIVATING FACTOR (PAF) IN NORMAL HUMAN-SALIVA
    COX, CP
    JORGENSEN, R
    WARDLOW, ML
    FARR, RS
    FEDERATION PROCEEDINGS, 1981, 40 (03) : 1021 - 1021
  • [43] PLATELET-ACTIVATING FACTOR (PAF) AND NEONATAL HYPOXIC PULMONARY VASOCONSTRICTION (HPV)
    STAMBOULY, J
    BRADLEY, L
    GOLDSTEIN, R
    PEDIATRIC RESEARCH, 1989, 25 (04) : A245 - A245
  • [44] The actions, detection and synthesis of platelet-activating factor (PAF) in mammalian pregnancy
    Liu Yutang
    Sui Shuqin
    Sun Zhongwu
    Bi Bing
    Xu Cuiqing
    Journal of Forestry Research, 1998, 9 (4) : 283 - 287
  • [45] EFFECT OF PLATELET-ACTIVATING FACTOR (PAF) AND SYNTHETIC ANALOGS ON FIBRINOLYSIS IN RATS
    HOFMANN, B
    MEISGEIER, U
    GREINER, J
    KERTSCHER, HP
    OSTERMANN, G
    FIBRINOLYSIS, 1990, 4 (04) : 247 - 252
  • [46] Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis
    Abeck, D
    Andersson, T
    Grosshans, E
    Jablonska, S
    Kragballe, K
    Vahlquist, A
    Schmidt, T
    Dupuy, P
    Ring, J
    ACTA DERMATO-VENEREOLOGICA, 1997, 77 (06) : 449 - 451
  • [47] The evidence of platelet-activating factor (PAF) in otitis media with effusion (OME)
    Furukawa, M
    RECENT ADVANCES IN OTITIS MEDIA, PROCEEDINGS, 2001, : 71 - 79
  • [48] EFFECT OF PLATELET-ACTIVATING FACTOR (PAF) ON HUMAN CARDIAC-MUSCLE
    ALLOATTI, G
    MONTRUCCHIO, G
    MARIANO, F
    TETTA, C
    DEPAULIS, R
    MOREA, M
    RAGNI, R
    CAMUSSI, G
    AGENTS AND ACTIONS, 1985, 16 (06): : 637 - 637
  • [49] PLATELET-ACTIVATING FACTOR (PAF-ACETHER) - HISTORICAL BACKGROUND AND DEFINITION
    BENVENISTE, J
    AGENTS AND ACTIONS, 1982, 12 (5-6): : 700 - 701
  • [50] Neuronal cytoskeletal alterations evoked by a platelet-activating factor (PAF) analogue
    McNeil, RS
    Swann, JW
    Brinkley, BR
    Clark, GD
    CELL MOTILITY AND THE CYTOSKELETON, 1999, 43 (02): : 99 - 113
12345